Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Depreciation & Amortization (CF): 2011-2025

Historic Depreciation & Amortization (CF) for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $608,000.

  • Abeona Therapeutics' Depreciation & Amortization (CF) rose 24.85% to $608,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 13.75%. This contributed to the annual value of $2.0 million for FY2024, which is 12.41% down from last year.
  • Per Abeona Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $608,000 for Q3 2025, which was up 11.76% from $544,000 recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Depreciation & Amortization (CF) peaked at $824,000 during Q2 2021, and registered a low of $487,000 during Q2 2024.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $534,000 (2025), whereas its average is $543,455.
  • Per our database at Business Quant, Abeona Therapeutics' Depreciation & Amortization (CF) tumbled by 60.44% in 2021 and then rose by 24.85% in 2025.
  • Abeona Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $807,000 in 2021, then dropped by 9.67% to $729,000 in 2022, then plummeted by 32.65% to $491,000 in 2023, then climbed by 9.78% to $539,000 in 2024, then climbed by 24.85% to $608,000 in 2025.
  • Its Depreciation & Amortization (CF) was $608,000 in Q3 2025, compared to $544,000 in Q2 2025 and $534,000 in Q1 2025.